tradingkey.logo

Integra Lifesciences Holdings Corp

IART
12.660USD
+0.070+0.56%
收盘 12/24, 13:00美东报价延迟15分钟
985.39M总市值
亏损市盈率 TTM

Integra Lifesciences Holdings Corp

12.660
+0.070+0.56%

关于 Integra Lifesciences Holdings Corp 公司

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.

Integra Lifesciences Holdings Corp简介

公司代码IART
公司名称Integra Lifesciences Holdings Corp
上市日期Aug 16, 1995
CEOPoul (Mojdeh)
员工数量4396
证券类型Ordinary Share
年结日Aug 16
公司地址1100 Campus Road
城市PRINCETON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编08540
电话16092750500
网址https://www.integralife.com/
公司代码IART
上市日期Aug 16, 1995
CEOPoul (Mojdeh)

Integra Lifesciences Holdings Corp公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.59M
-11.20%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%
Mr. Harvinder Singh
Mr. Harvinder Singh
Executive Vice President, President - International Business
Executive Vice President, President - International Business
21.94K
+65.53%
Ms. Mojdeh Poul
Ms. Mojdeh Poul
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Shaundra D. Clay
Ms. Shaundra D. Clay
Independent Director
Independent Director
--
--
Mr. Chris Ward
Mr. Chris Ward
IR Contact Officer
IR Contact Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.59M
-11.20%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Neurosurgery
208.99M
50.29%
Wound Reconstruction and Care
84.75M
20.39%
Private Label
26.90M
6.47%
地区USD
名称
营收
占比
United States
306.31M
73.70%
Asia Pacific
47.73M
11.48%
Europe
42.59M
10.25%
Rest of World
18.97M
4.56%
业务
地区
业务USD
名称
营收
占比
Neurosurgery
208.99M
50.29%
Wound Reconstruction and Care
84.75M
20.39%
Private Label
26.90M
6.47%

股东统计

更新时间: 11月15日 周六
更新时间: 11月15日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.36%
Fuller & Thaler Asset Management Inc.
5.03%
其他
52.94%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.36%
Fuller & Thaler Asset Management Inc.
5.03%
其他
52.94%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
36.53%
Investment Advisor
36.42%
Hedge Fund
18.48%
Corporation
10.93%
Individual Investor
3.20%
Research Firm
2.31%
Pension Fund
1.49%
Bank and Trust
0.44%
Sovereign Wealth Fund
0.04%

机构持股

更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
583
73.55M
94.42%
-25.07M
2025Q2
600
89.38M
114.72%
-18.72M
2025Q1
635
87.01M
111.97%
-18.30M
2024Q4
636
81.93M
106.10%
-20.27M
2024Q3
638
82.93M
106.93%
-12.58M
2024Q2
628
84.82M
107.92%
-1.75M
2024Q1
613
79.36M
101.18%
-3.69M
2023Q4
597
79.81M
101.26%
-5.74M
2023Q3
592
81.88M
100.31%
-3.94M
2023Q2
587
82.30M
100.29%
-6.57M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
9.43M
12.11%
-322.52K
-3.31%
Jun 30, 2025
TRU ST Partnership, L.P.
8.52M
10.93%
--
--
Feb 28, 2025
Rubric Capital Management LP
7.35M
9.44%
+2.71M
+58.36%
Jun 30, 2025
The Vanguard Group, Inc.
7.50M
9.63%
+34.14K
+0.46%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
3.89M
5%
-29.99K
-0.76%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.92M
3.74%
+333.71K
+12.91%
Jun 30, 2025
Invesco Advisers, Inc.
3.18M
4.08%
+51.84K
+1.66%
Jun 30, 2025
State Street Investment Management (US)
2.83M
3.63%
+79.03K
+2.88%
Jun 30, 2025
Boston Management and Research
2.74M
3.52%
--
--
Jun 30, 2025
Paradigm Capital Management, Inc.
2.18M
2.8%
+796.30K
+57.49%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
1.44%
State Street SPDR S&P Health Care Equipment ETF
1.39%
ROBO Global Healthcare Technology & Innovation ETF
1.02%
Invesco S&P SmallCap Health Care ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.43%
Inspire Small/Mid Cap ESG ETF
0.19%
Royce Quant Small-Cap Quality Value ETF
0.13%
Principal U.S. Small-Cap ETF
0.13%
iShares S&P Small-Cap 600 Value ETF
0.12%
State Street SPDR S&P 600 Small Cap Value ETF
0.11%
查看更多
iShares Neuroscience and Healthcare ETF
占比1.44%
State Street SPDR S&P Health Care Equipment ETF
占比1.39%
ROBO Global Healthcare Technology & Innovation ETF
占比1.02%
Invesco S&P SmallCap Health Care ETF
占比0.49%
Invesco NASDAQ Future Gen 200 ETF
占比0.43%
Inspire Small/Mid Cap ESG ETF
占比0.19%
Royce Quant Small-Cap Quality Value ETF
占比0.13%
Principal U.S. Small-Cap ETF
占比0.13%
iShares S&P Small-Cap 600 Value ETF
占比0.12%
State Street SPDR S&P 600 Small Cap Value ETF
占比0.11%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Integra Lifesciences Holdings Corp的前五大股东是谁?

Integra Lifesciences Holdings Corp 的前五大股东如下:
BlackRock Institutional Trust Company, N.A.持有股份:9.43M,占总股份比例:12.11%。
TRU ST Partnership, L.P.持有股份:8.52M,占总股份比例:10.93%。
Rubric Capital Management LP持有股份:7.35M,占总股份比例:9.44%。
The Vanguard Group, Inc.持有股份:7.50M,占总股份比例:9.63%。
Fuller & Thaler Asset Management Inc.持有股份:3.89M,占总股份比例:5.00%。

Integra Lifesciences Holdings Corp的前三大股东类型是什么?

Integra Lifesciences Holdings Corp 的前三大股东类型分别是:
BlackRock Institutional Trust Company, N.A.
TRU ST Partnership, L.P.
Rubric Capital Management LP

有多少机构持有Integra Lifesciences Holdings Corp(IART)的股份?

截至2025Q3,共有583家机构持有Integra Lifesciences Holdings Corp的股份,合计持有的股份价值约为73.55M,占公司总股份的94.42%。与2025Q2相比,机构持股有所增加,增幅为-20.30%。

哪个业务部门对Integra Lifesciences Holdings Corp的收入贡献最大?

在FY2025Q2,Neurosurgery业务部门对Integra Lifesciences Holdings Corp的收入贡献最大,创收208.99M,占总收入的50.29%。
KeyAI